The new patents include:
- Hong Kong patent (HK1098450) for the proprietary process technology behind the Ocufors formulation and ophthalmic applications thereof. The process steps delineate a method of solubilising diterpenes using Randomly Methylated Beta Cyclodextrins (RAMEBCD).
- Ocufors was also the subject of the Canadian Patent 2537820. This patent discusses a unique proprietary methodology to solubilize diterpenes like forskolin using randomly methylated cyclodextrins. The patented solubilization method enhances the application of diterpenes in ophthalmic therapy.
- New Zealand issued patent NZ598630 for the proprietary Saberry and Cococin synergisticformulation and its protective effect on the dermal papilla cells. It is note worthy that this invention earlier had been awarded the US Patent (US8247003).
- PteroWhite was awarded the DPR Korea Patent 1011504. The patent discusses the ability of pterostilbene to modulate melanogenesis and skin hyper pigmentation.
- U.S. patent (US8394852) for the inotilone derivatives (composition of matter). The invention delves into the synthetic routes for derivatives of 5-methyl-3(2H)-furanone compounds, compositions of matter and biological applications thereof.
- U.S. patent (US8383594) for OLEPENT. The invention titled “Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceuticals” is specifically directed to a unique pentapeptide linked chemically to the plant derived Oleanolic acid and cosmetic compositions thereof. With a proven potential for regenerating the dermal matrix OLEPENT is considered a technological breakthrough in the cosmeceutical sector, more specifically in the Anti-aging range of ingredients.
- European Patent EP1791423 for BOSWELLIN. The patent discusses the unique therapeutic potential of boswellic acids in combination with selenium amino acids to effectively manage inflammatory conditions of immunological origin like psoriasis.